蛋白质溶解向金梅拉 (PROTAC):当前的应用和未来的方向
Gang Fan1,2, Shilin Chen3,2, Qingping Zhang4,2
1Medical Research Center Affiliated Nanshan Hospital of Shenzhen University Shenzhen China.
MedComm
|October 6, 2025
概括
针对性蛋白质降解 (TPD) 通过积极去除疾病蛋白质,彻底改变了药物发现. 针对蛋白质溶解的嵌合体 (PROTACs) 对具有挑战性的目标和复杂疾病取得了显著的临床进展.
科学领域:
- 药物发现和开发 药物发现和开发
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 针对性蛋白质降解 (TPD) 通过积极消除疾病驱动蛋白质,提供了一种新的治疗策略,与传统的抑制不同.
- 这种方法扩大了以前无法治疗的点的治疗选择,包括转录因子 (MYC,STAT3) 和突变蛋白 (KRAS G12C).
- 化向化体 (PROTACs) 是领先的TPD平台,临床试验显示显著的进展.
研究的目的:
- 在各种治疗领域全面审查PROTAC的发展.
- 分析关键目标并评估突破性PROTAC候选人的临床进展.
- 讨论复杂疾病的 PROTAC 技术的挑战和未来方向.
主要方法:
- 审查关于PROTAC开发和临床试验的现有文献.
- 分析针对酶,激素受体,抗apoptotic 蛋白质和表观遗传调节器的 PROTAC 应用程序.
- 对ARV-110,ARV-471和BTK降解剂等候选药物的临床数据的评估.
主要成果:
- 对于MYC,STAT3,KRAS G12C和BTK等目标,PROTAC正在临床上取得进展.
- 在前列腺癌 (ARV-110) 和乳腺癌 (ARV-471) PROTACs中,成功的临床进展被注意到.
- 确定了诸如"效应"和口服生物可用性限制等关键挑战.
结论:
- PROTAC技术代表了药物发现的范式转变,使得以前难以处理的蛋白质成为目标.
- 在输送策略,组织特异性设计和E3结合酶扩张方面的持续创新对于克服挑战至关重要.
- PROTACs具有显著的潜力,可以改变对常规疗法耐药的复杂疾病的治疗.
相关概念视频
Tagging and Fusion Proteins
8.3K
Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
8.3K
Conservative Site-specific Recombination and Phase Variation
6.6K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
6.6K


